HealthcareServices

Single Nucleotide Polymorphism (SNP) Genotyping Market Outlook 2026–2030: Key Business Drivers and Trends

March 5, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the single nucleotide polymorphism (snp) genotyping market from 2026–2035 with trusted insights from The Business Research Company

By how much is the Single Nucleotide Polymorphism (SNP) Genotyping Market expected to grow between 2026 and 2030?

The single nucleotide polymorphism (snp) genotyping market has experienced rapid expansion in recent years. Projections indicate it will increase from $12.34 billion in 2025 to $14.69 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 19.1%. Historically, this expansion has been driven by factors such as limited early-stage genotyping capabilities, an escalating demand in research, the elevated expense of genomic analysis, increasing collaborations between research laboratories, and the initial integration into pharmacogenomics.

The single nucleotide polymorphism (snp) genotyping market size is anticipated to undergo substantial expansion in the coming years. By 2030, it is projected to reach $29.74 billion, exhibiting a compound annual growth rate (CAGR) of 19.3%. This projected growth throughout the forecast period stems from factors such as the advancement of high-throughput SNP platforms, a rise in its application within personalized medicine, the incorporation of AI for predictive analysis, its increasing use in clinical diagnostics, and the expansion of agricultural genomics applications. Furthermore, significant trends expected during this period include its integration with pharmacogenomics, an increase in disease risk prediction, broader application in agriculture and animal breeding, the wider adoption of microarray-based genotyping, and the emergence of point-of-care SNP testing.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12569&type=smp

Which Drivers Are Influencing Market Acceleration In The Single Nucleotide Polymorphism (SNP) Genotyping Market?

The single nucleotide polymorphism (SNP) genotyping market is projected to expand due to the escalating burden of chronic conditions, which are health issues persisting for a year or more, often requiring continuous medical management or limiting daily activities. Given the rising incidence of these conditions, single-nucleotide polymorphism (SNP) genotyping becomes vital for pinpointing genetic predispositions and fostering personalized medicine. As an illustration, data from the Centers for Disease Control and Prevention (CDC) in April 2025 revealed that in 2023, roughly 194 million U.S. adults, or 76.4%, reported living with at least one chronic condition. This included 59.5% of young adults, 78.4% of midlife adults, and 93.0% of older adults. Thus, the increasing burden of chronic conditions is a key factor propelling the single nucleotide polymorphism (SNP) genotyping systems market forward.

What Leading Segments Are Studied In The Single Nucleotide Polymorphism (SNP) Genotyping Market?

The single nucleotide polymorphism (snp) genotyping market covered in this report is segmented –

1) By Product: Consumables, Instruments, Services

2) By Technology: TaqMan SNP Genotyping, Mass Array SNP Genotyping, SNP Gene Chip Arrays, Other Technologies

3) By Application: Animal Genetics, Plant Improvement, Diagnostic Research, Pharmaceuticals And Pharmacogenomics, Agricultural Biotechnology, Other Applications

Subsegments:

1) By Consumables: Reagents And Kits, DNA Probes, Microarrays

2) By Instruments: SNP Genotyping Platforms, Sequencers, PCR Machines

3) By Services: SNP Genotyping Services, Data Analysis Services, Consultation Services

Which Trends Are Guiding The Evolution Of The Single Nucleotide Polymorphism (SNP) Genotyping Market?

Major companies operating in the single nucleotide polymorphism (SNP) genotyping market are concentrating on creating biomarkers valuable for coronary heart disease detection to enhance their market profitability. Single nucleotide polymorphism (SNP) biomarkers linked to coronary heart disease (CHD) detection represent specific genetic variations discovered through genomic research, which are associated with an increased risk or susceptibility to coronary heart disease. For instance, in February 2023, Cardio Diagnostics, a US-based biotechnology company, introduced PrecisionCHD. PrecisionCHD is an AI-powered blood test that employs a combination of epigenetic (DNA methylation) and genetic (single nucleotide polymorphism) biomarkers for CHD detection. The test leverages a machine-learning model to achieve over 75% sensitivity for both genders, offering a non-invasive choice for blood sample collection either in-office or at home. This innovation removes the requirement for conventional tests such as stress tests, ensuring objectivity by solely depending on biomarkers, rather than self-reported patient data.

Which Major Industry Participants Are Leading The Single Nucleotide Polymorphism (SNP) Genotyping Market Growth?

Major companies operating in the single nucleotide polymorphism (snp) genotyping market are Thermo Fischer Scientific Inc, Danaher Corporation, Roche Diagnostics Corporation, GE HealthCare Technologies Inc, Eurofins Genomics LLC, Beckman Coulter Inc, Bio-Rad Laboratories Inc, Qiagen N.V, Sigma-Aldrich Corporation, Agilent Technologies Inc, PerkinElmer Inc, Illumina Inc, Promega Corporation, GenScript Biotech Corporation, Integrated DNA Technologies Inc, LGC Ltd, Sequenom Inc, Fluidigm Corporation, Oxford Gene Technology, Affymetrix Inc, PREMIER Biosoft International Inc, Rubicon Genomics, Xcelris Genomics, Douglas Scientific LLC, Golden Helix Inc

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/single-nucleotide-polymorphism-snp-genotyping-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Single Nucleotide Polymorphism (SNP) Genotyping Market?

North America was the largest region in the single nucleotide polymorphism (SNP) genotyping market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the single nucleotide polymorphism (snp) genotyping market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Single Nucleotide Polymorphism (SNP) Genotyping Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12569&type=smp

Browse Through More Reports Similar to the Global Single Nucleotide Polymorphism (SNP) Genotyping Market 2026, By The Business Research Company

Genomics Market Report 2026

https://www.thebusinessresearchcompany.com/report/genomics-global-market-report

Genotyping Market Report 2026

https://www.thebusinessresearchcompany.com/report/genotyping-global-market-report

Genotyping Assay Market Report 2026

https://www.thebusinessresearchcompany.com/report/genotyping-assay-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795